Literature DB >> 16274336

Treatment options and paradigms in childhood temporal lobe epilepsy.

Amit Ray1, Elaine Wyllie.   

Abstract

Temporal lobe epilepsy in adults is a relatively homogenous syndrome with hippocampal sclerosis being its most common pathologic substrate. In the pediatric age group, low-grade neoplasms and cortical dysplasia are much more common than hippocampal sclerosis. Pediatric temporal lobe epilepsy has distinct semiologic, electrophysiologic and imaging characteristics as compared with its adult counterpart. The various treatment options for pediatric temporal lobe epilepsy include antiepileptic drugs, resective surgery, vagal nerve stimulation and the ketogenic diet. In spite of the multiple antiepileptic drugs currently available, 5-10% of all newly diagnosed cases will remain intractable to medical therapy and should be referred for presurgical evaluation. Resective surgery offers the best chance of seizure freedom in carefully selected patients. Future areas of research include new drug development, better imaging and localization techniques, and brain stimulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274336     DOI: 10.1586/14737175.5.6.785

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Comparison of temporal lobectomies of children and adults with intractable temporal lobe epilepsy.

Authors:  Yun Jin Lee; Hoon-Chul Kang; Sun Joon Bae; Heung Dong Kim; Jeong Tae Kim; Byung In Lee; Kyoung Heo; Jin Woo Jang; Dong Seok Kim; Tae Seung Kim; Joon Soo Lee
Journal:  Childs Nerv Syst       Date:  2009-11-10       Impact factor: 1.475

2.  Temporal lobe epilepsy surgery in children versus adults: from etiologies to outcomes.

Authors:  Yun-Jin Lee; Joon Soo Lee
Journal:  Korean J Pediatr       Date:  2013-07-19

Review 3.  Metabolic Therapy for Temporal Lobe Epilepsy in a Dish: Investigating Mechanisms of Ketogenic Diet using Electrophysiological Recordings in Hippocampal Slices.

Authors:  Masahito Jr Kawamura; David N Ruskin; Susan A Masino
Journal:  Front Mol Neurosci       Date:  2016-11-01       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.